Prescription drug abuse is an epidemic in the US and a chronic brain disease, but it is not treated the way other chronic conditions are, said Kelly J. Clark, MD, MBA, president elect of the American Society of Addiction Medicine.
Prescription drug abuse is an epidemic in the US and a chronic brain disease, but it is not treated the way other chronic conditions are, said Kelly J. Clark, MD, MBA, president elect of the American Society of Addiction Medicine.
Transcript (slightly modified)
What is the scope of the addiction problem in the US today?
The scope of the addiction problem is epidemic. The CDC has called prescription drug abuse an epidemic and they don’t use that term lightly. More Americans die from unintentional overdose than die from motor vehicle accidents.
We’ve found now that the abuse of opioids, unintentional overdose deaths, have actually decreased the anticipated lifespan of a segment of Americans—particularly, middle-aged white women. The scope of this problem is enormous. We have about 2 people in this country die every hour from opioid overdose.
Why isn’t addiction viewed similarly to other chronic conditions and how do we change that narrative?
Addiction was treated the way many central nervous system (CNS) diseases have been treated in the past, which is as a moral failing or even a curse. Something is wrong with the person, culturally from our background, who has an addictive disease. We used to stigmatize people who had Parkinson’s disease—tremors—who had other CNS illnesses, like dementia. And we don’t really do that anymore with diseases other than the disease of addiction.
We’ve also had this construct of addiction as being a moral failing that people can just get over or pull themselves up by their boostraps. And we really have a construct now, as doctors, as medical professionals, that addiction is a chronic brain disease.
It’s very hard, though, to get people throughout the entire population to understand that, particularly people who are well aware of our traditional 12-step modalities, which is a spiritual approach and has worked for millions of people in treating their alcoholism. We’ve found that the approach that worked for treating alcoholism has not worked as well for treating opioid addiction.
And we as a society have been hesitant to follow what evidence-based medicine shows us about treating opioid addiction, which is particularly the use of medications in an ongoing way—the way you would any other chronic disease state.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More